Get the Stockscreener App
11.42
0.00%
0.00
Intellia Therapeutics Inc stock is traded at $11.42, with a volume of 3.33M.
It is up +0.00% in the last 24 hours and up +5.16% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$11.42
Open:
$11.38
24h Volume:
3.33M
Relative Volume:
0.74
Market Cap:
$1.23B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-2.0839
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
-5.31%
1M Performance:
+5.16%
6M Performance:
+18.71%
1Y Performance:
-44.75%
1-Day Range:
$11.17
$11.64
1-Week Range:
$10.88
$12.30
52-Week Range:
$5.90
$23.76
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
11.42 | 1.21B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Polar Asset Management Partners Inc. Sells 250,354 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Zacks Research Has Optimistic Outlook of NTLA Q3 Earnings - MarketBeat
Granahan Investment Management LLC Has $3.38 Million Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Russell Investments Group Ltd. Sells 109,064 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% - AOL.com
Exclusive: Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study - Endpoints News
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 7.5%What's Next? - MarketBeat
Can Traders Expect Breakout From Intellia Therapeutics Inc. This WeekJuly 2025 Rallies & Reliable Volume Spike Trade Alerts - beatles.ru
Real time alert setup for Intellia Therapeutics Inc. performanceJuly 2025 Momentum & Reliable Intraday Trade Plans - Newser
Using data tools to time your Intellia Therapeutics Inc. exitEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Signal strength of Intellia Therapeutics Inc. stock in tech scannersQuarterly Trade Summary & Free Verified High Yield Trade Plans - Newser
Intellia Therapeutics, Inc. $NTLA Shares Acquired by PDT Partners LLC - MarketBeat
Is Intellia Therapeutics Inc. stock a smart retirement pickJuly 2025 Gainers & Safe Entry Momentum Stock Tips - خودرو بانک
Armistice Capital LLC Invests $2.59 Million in Intellia Therapeutics, Inc. $NTLA - MarketBeat
What’s next for Intellia Therapeutics Inc. stockMarket Weekly Review & Daily Profit Maximizing Trade Tips - خودرو بانک
Risk Check: Will Intellia Therapeutics Inc. outperform tech stocksQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Is Intellia Therapeutics Inc. benefiting from interest rate changes2025 Retail Activity & Stepwise Swing Trade Plans - خودرو بانک
Is Intellia Therapeutics Inc. building a consolidation basePortfolio Risk Summary & Long-Term Safe Investment Plans - Newser
How hedge fund analytics apply to Intellia Therapeutics Inc. stockTrade Exit Report & Safe Entry Zone Identification - Newser
Will Intellia Therapeutics Inc. stock hit new highs in YEARGlobal Markets & Weekly High Momentum Picks - خودرو بانک
Chart based analysis of Intellia Therapeutics Inc. trendsTrend Reversal & Stepwise Trade Execution Plans - Newser
Published on: 2025-09-05 05:28:03 - Newser
Chart based exit strategy for Intellia Therapeutics Inc.July 2025 Market Mood & Real-Time Stock Movement Alerts - Newser
How to forecast Intellia Therapeutics Inc. trends using time series2025 Price Targets & Free Technical Confirmation Trade Alerts - Newser
Pattern recognition hints at Intellia Therapeutics Inc. upsideLayoff News & Smart Allocation Stock Reports - Newser
ARK Investment Expands Stake in Intellia Therapeutics (NTLA) - GuruFocus
Published on: 2025-09-04 03:41:57 - Newser
Intellia Therapeutics, Inc. $NTLA Holdings Trimmed by Second Line Capital LLC - MarketBeat
Multi asset correlation models including Intellia Therapeutics Inc.2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
Why Intellia Therapeutics Inc. is moving todayTrade Volume Summary & Reliable Volume Spike Trade Alerts - Newser
Is Intellia Therapeutics Inc. stock reversal real or fakeCEO Change & Consistent Profit Trade Alerts - Newser
Cathie Wood’s ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia - Investing.com
Panic Selling: Is Intellia Therapeutics Inc. benefiting from interest rate changesJuly 2025 Drop Watch & Verified High Yield Trade Plans - خودرو بانک
Does Intellia Therapeutics Inc. stock have upside surprise potentialJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک
Intellia Therapeutics Inc. stock outlook for YEARPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
Leading vs lagging indicators on Intellia Therapeutics Inc. performanceWall Street Watch & Fast Gaining Stock Strategy Reports - Newser
What the charts say about Intellia Therapeutics Inc. todayPortfolio Value Report & Stepwise Swing Trade Plans - Newser
Tema Etfs LLC Has $189,000 Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Tools to assess Intellia Therapeutics Inc.’s risk profileQuarterly Trade Report & Expert Verified Stock Movement Alerts - Newser
Merger Talk: Is Intellia Therapeutics Inc. benefiting from interest rate changesEarnings Performance Report & Stepwise Trade Signal Implementation - خودرو بانک
Will Intellia Therapeutics Inc. outperform tech stocksMarket Activity Report & Technical Buy Zone Confirmation - خودرو بانک
Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus - Nasdaq
Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider - GlobeNewswire Inc.
Intellia Therapeutics Inc. Stock Flags Risk Zone in Volatility Index getLinesFromResByArray error: size == 0 - thegnnews.com
Aug Levels: What’s next for Intellia Therapeutics Inc. stockInsider Selling & Short-Term Trading Opportunity Alerts - خودرو بانک
Intellia Therapeutics, Inc. $NTLA Shares Acquired by AlphaQuest LLC - MarketBeat
Why is Intellia Therapeutics Inc. stock going upJuly 2025 Update & High Accuracy Trade Signal Alerts - خودرو بانک
Is Intellia Therapeutics Inc. stock good for income investorsPortfolio Performance Report & Consistent Profit Trade Alerts - خودرو بانک
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
| Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):